[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indirect-hyperbilirubinemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indirect-hyperbilirubinemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652316","efficacy-of-bifidobacterium-animalis-subsp-lactis-in-the-treatment-of-indirect-hyperbilirubinemia-in-term-neonates-100652316",false,"NCT07773012","Efficacy of Bifidobacterium Animalis Subsp. Lactis in the Treatment of Indirect Hyperbilirubinemia in Term Neonates","Efficacy of Bifidobacterium Animalis Subsp. Lactis as an Adjunct to Phototherapy in the Treatment of Indirect Hyperbilirubinemia in Term Neonates","Inclusion Criteria:\n\n* Age from 0-28 days.\n* Gestational age 37-42 weeks.\n* Diagnosed with indirect hyperbilirubinemia according to the AAP 2022 guidelines.\n* Eligible for phototherapy based on serum total bilirubin levels\n* Informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Direct hyperbilirubinemia (direct bilirubin \\>2.0 mg\u002FdL and \\>20% of total serum bilirubin).\n* Major congenital anomalies or severe concurrent illness (e.g., respiratory failure, intracranial hemorrhage).\n* Indication for exchange transfusion, intravenous immunoglobulin (IVIG) or phenobarbital according to the AAP 2022 guidelines.\n* Neonatal sepsis, blood group incompatibility, glucose-6-phosphate dehydrogenase deficiency, red blood cell membrane disorders.\n* Suspected gastrointestinal obstruction.\n* Unable to tolerate oral feeding.","ALL","28 Days",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effectiveness of adjunctive oral Bifidobacterium animalis subsp. lactis in term neonates with indirect hyperbilirubinemia receiving phototherapy. The study will compare the effects of adjunctive probiotics plus standard phototherapy with standard phototherapy alone on the duration of phototherapy, length of hospital stay, serum total bilirubin reduction, phototherapy-related adverse events, and hospital readmission after discharge.",[26],"Indirect Hyperbilirubinemia",[28,29,30,31],"Neonatal jaundice","Indirect hyperbilirubinemia","Phototherapy","Probiotics","NOT_YET_RECRUITING","2026-08-14",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2028-05-31",{"name":42,"class":43},"Can Tho University of Medicine and Pharmacy","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":17,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100600849","phase-2-comparison-of-zinc-and-probiotics-on-neonates-with-indirect-hyperbilirubinemia-undergoing-phototherapy-100600849","NCT07102836","COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","COMPARATIVE EFFECTS OF ZINC AND PROBIOTICS ON NEONATAL INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","ZIPP","Inclusion Criteria:\n\n* 1\\. Term or Near term neonates 2. Age \\\u003C7 days at enrollment 3. Bilirubin levels within phototherapy range according to NICE bilirubin threshold charts 4. No identifiable pathology 5. Tolerating oral feeds 6. Parental or Guardian written informed consent taken.\n\nExclusion Criteria:\n\n* 1\\. Positive sepsis screen or clinical signs of infection 2. Direct hyperbilirubinemia 3. Gastrointestinal malformations 4. Oral intolerance 5. Requiring mechanical ventilation 6. Congenital anomalies 7. Parental or Guardian refusal to participate in study","0 Days",{"count":55,"type":20},110,[57],"PHASE2","Study will evaluate effects of oral zinc and probiotics supplementation in neonates who have indirect hyperbilirubinemia and are receiving phototherapy. Aim is to compare efficacy of these two drugs in clearing bilirubin and reducing duration of phototherapy. Neonates will be randomly assigned to receive either drug alongside phototherapy.",[26,60],"Neonatal",[62,31,63,30,64,65,66,67,26],"Zinc","Jaundice","Neonates","Randomized Controlled Trial","Bilirubin","Enterohepatic Circulation","RECRUITING","2025-07-30",{"date":71,"type":36},"2025-08-05",{"date":73,"type":20},"2025-08-07",{"date":75,"type":20},"2026-05-07",{"name":77,"class":43},"Quaid-e-Azam Medical College"]